• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nuclea signs two partnership agreements, expands service offerings

Nuclea signs two partnership agreements, expands service offerings

January 15, 2014
CenterWatch Staff

Pittsfield, Mass.-based Nuclea Biotechnologies has signed two development deals that will expand its service offering to include CLIA validation. The deals signed with AccuGenomics, a diagnostic company focused on developing standardized molecular diagnostic tests in oncology, and Nuvera Biosciences will include validating two new assays in the treatment of chronic myeloid leukemia (CML) and breast cancer. The deals include the manufacturing and selling of kits for one assay, and offering both assays in their CLIA laboratory.

The agreement with AccuGenomics soon will lead to more effective treatments for those diagnosed with CML. Nuclea will participate in the co-development of the BCR-abl diagnostic assay and will validate the test so it can be used in a clinical lab.

Nuclea will manufacture the AccuGenomics BCR-abl Molecular Diagnostic Kit in its new GMP facility, sell the research use only (RUO) kits and offer the test in their CLIA laboratory. Nuclea also will develop and submit an IVD product to the FDA for approval.

After patients receive bone marrow transplants, they need to be continuously monitored. The BCR-abl test is able to monitor efficiency of treatment, residual disease and disease relapse in those CML patients with a BCR-abl MBCR fusion gene event between oncogenes. Currently, there is a dry test available on the market. However, the BCR-abl test is chromosomal, and provides faster and more accurate results than other tests currently available.

 “Nuclea will manufacture the kits, market the assay and include the test in our portfolio offered through our CLIA lab,” said Patrick Muraca, president and CEO of Nuclea.

“The co-development agreement for our standardized BCR-abl CLIA test in bone marrow and blood samples with Nuclea is very promising as it relates to our diagnostic strategy,” said Dr. Nick Lazaridis, president of AccuGenomics. “The partnership with Nuclea provides extensive manufacturing experience aligned with a cutting edge oncology laboratory offering the standardized BCR-abl test utilizing our proprietary SNAQ technology to the Northeast market.”

The deal with Nuvera centers on the co-development of their gene-based breast cancer assay which can predict patient responsiveness to taxane chemotherapy and endocrine therapy. The test is a genomic predictor of response and survival following taxane-Anthracycline chemotherapy for invasive breast cancer. The patient response to these treatment options is a tool for the management and monitoring of women with breast cancer.

Nuclea will conduct the development of the assay, along with securing CLIA validation, beginning February.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing